Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Adrenoleukodystrophy - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Adrenoleukodystrophy - Pipeline ...

A seven-year Dutch study shows that a single baseline blood measurement of neurofilament light chain predicts the pace of ...

Adrenoleukodystrophy is a rare condition associated with abnormalities in myelin, the white matter that protects nerve fibers in the spinal cord and brain. It occurs due to a mutation on the X ...

Wilmington, Delaware, United States, Transparency Market Research Inc. , Feb. 14, 2025 (GLOBE NEWSWIRE) -- The global adrenoleukodystrophy drugs market (Markt für Medikamente gegen ...

Neuraxpharm Group and Minoryx Therapeutics, today announce that the European Commission (EC) has granted marketing authorization under exceptional circumstances for NEZGLYAL® (leriglitazone), an ...

Cerebral adrenoleukodystrophy is a severe form of X-linked adrenoleukodystrophy characterized by white-matter disease, loss of neurologic function, and early death. Elivaldogene autotemcel (eli-cel) ...

X-linked adrenoleukodystrophy (X-ALD) is caused by a defect in the gene ABCD1, which maps to Xq28 and codes for a peroxisomal membrane protein that is a member of the ...

Neuraxpharm Group and Minoryx Therapeutics today announce that the European Commission (EC) has granted marketing authorisation under exceptional circumstances for NEZGLYAL ® (leriglitazone), an ...